Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2022-10-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
EXCHANGE NOTICE - TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a short notice from the Hong Kong Stock Exchange (HKEX) announcing a trading halt for Immunotech Biopharm Ltd. It does not contain financial statements, management reports, or specific regulatory filings that fit into the other categories. As it is a general regulatory announcement regarding market activity, it falls under the RNS category.
2022-10-31 English
PROPOSED ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND CALL OPTION DEED BY A SUBSTANTIAL SHAREHOLDER
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed issue of convertible bonds by Immunotech Biopharm Ltd. It details the subscription agreement, principal terms of the convertible bonds, conditions precedent, and call option deed by a substantial shareholder. The content focuses on financing activities, including bond issuance terms, conversion price, security, and redemption. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a brief factsheet or a presentation but a detailed announcement of a capital raising transaction. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed terms support that this is the actual announcement, not just a notice or report publication announcement.
2022-10-30 English
VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY A DIRECTOR AND CONTROLLING SHAREHOLDER
Director's Dealing Classification · 95% confidence The document is a voluntary announcement by Immunotech Biopharm Ltd regarding an increase in shareholding by a director and controlling shareholder, Mr. Tan Zheng. It details the acquisition of shares by Mr. Tan's investment holding company and the resulting shareholding percentages. The document does not contain financial statements, earnings data, or detailed financial analysis. It is focused on shareholding changes by a director, which fits the definition of Director's Dealing filings. The document length is 4017 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-10-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return report on movements in securities, specifically focusing on share capital, issued shares, share options, and related confirmations for Immunotech Biopharm Ltd. It is submitted to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content includes detailed tables on authorized and issued shares, share options, and confirmations by a company director. There is no indication of financial statements, earnings data, or management discussion. The document is regulatory in nature, reporting share capital and share option movements, which aligns with a Major Shareholding Notification or Share Issue/Capital Change. However, since it reports movements in issued shares and share options without new share issuance or repurchase, it fits best under Share Issue/Capital Change (SHA) as it details changes in share capital structure and share options. The document length (6433 characters) and detailed data confirm it is not a brief announcement but a substantive regulatory filing on share capital movements.
2022-10-07 English
2022 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 Interim Report' and contains detailed financial and operational data highlights, condensed consolidated financial statements, management discussion and analysis, and corporate information. It covers a six-month period ended 30 June 2022, which is typical for an interim or quarterly report. The presence of unaudited financial data, condensed financial statements, and management discussion confirms it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and related capital changes for Immunotech Biopharm Ltd. It includes data on share capital, share options, and confirmations related to share issuance. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is titled as a 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities.' This type of document is a regulatory filing that reports on share capital and share issuance movements, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. It is not an annual or interim report, nor a call transcript or AGM material. It is not a report publication announcement since it contains substantive data. The best fitting category is 'Share Issue/Capital Change' (SHA), as it details movements in issued shares, share options, and authorized capital changes.
2022-09-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.